Home' Australian Pharmacist : Australian Pharmacist July 2012 Contents 580 Australian Pharmacist July 2012 I ©Pharmaceutical Society of Australia Ltd.
We must take Daniel’s scenario as
an example of how important it is to
have policies in place and constructive
dialogue between professionals, not
as an excuse to stop providing OST
services. Pharmacists can and should
adopt problem solving skills to develop
policies to address complexities
they may encounter in the course of
offering the service. The return for
such services cannot be measured in
financial terms alone. There is much
value in the contribution pharmacy
has to the safety and well being of the
community, particularly in the provision
of OST services, and we as pharmacists
should take pride in it. That in itself is
1. Chaar B, Hanrahan J, Day C. Provision of Opioid Substitution
Therapy Services in Australian Pharmacies. Australasian
Medical Journal. 2011;4(4):210-6 .
2. Chaar B. The right of healthcare providers to refuse provision
of service: the case of pharmacy and illicit drug dependent
patients. Australian Journal of Professional and Applied Ethics.
3. National Drug Strategy. National Policy on Methadone
Treatment. Canberra: Australian Government Publishing
Service; 1998 [cited 2011, May]; Available from: http://www.
4. Australian Government Department of Health and Ageing
(DoHA). National Pharmacotherapy Policy for People
Dependent on Opioids. Canberra: Australian Government;
5. Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, et al. The
characteristics of heroin users entering treatment: Findings
from the Australian treatment outcome study (ATOS). Drug
and Alcohol Review. 2005;24(5):411-8 .
6. Luty J, Kumar P, Stagias K. Stigmatised attitudes in independent
pharmacies associated with discrimination towards individuals
with opioid dependence. Psychiatrist. 2010;34(12):511-4 .
7. The Pharmacy Guild of Australia New South Wales Branch.
Opioid Substitution Program Resource Manual. Standard
3 - Delivery of Health Programs and Services. Sydney: The
Pharmacy Guild of Australia (New South Wales Branch); 2011.
8. Fraser S, Valentine K, Treloar C, Macmillan K. Methadone
maintenance treatment in New South Wales and Victoria:
Takeaways, diversion and other key issues. Sydney: National
Centre in HIV Social Research;The University of New South
9. Nielsen S, Dietze P, Dunlop A, Muhleisen P, Lee N, Taylor D.
Buprenorphine supply by community pharmacists in Victoria,
Australia: Perceptions, experiences and key issues identified.
Drug and Alcohol Review. 2007;26(2):143-51.
10. Berbatis CG, Sunderland VB, Bulsara M, Mills C. Australia’s
community pharmacy survey: National Pharmacy Database
Project. In: The Commonwealth Department of Health and
Ageing & The Pharmacy Guild of Australia, editor. Perth: Curtin
University of Technology of Western Australia; 2003. p. 131.
Brooke Myers is a pharmacist Clinical
Educator Royal Brisbane Women’s
Hospital and Conjoint Lecturer University
Stockley’s Drug Interactions
Pocket Companion 2012
Reviewed by Brooke Myers
Stockley’s Drug Interactions Pocket
Companion 2012 provides a quick and
easy reference text for any pharmacist
(hospital, community or otherwise) on
over 1,900 interactions between specific
drugs, as well as widely recognised
Compiled from the most recent quarterly
update of Stockley’s Drug Interactions,
the information is presented as a
brief summary of the evidence for the
interaction and a description of how
best to manage it. An example is the
drug monograph for Digoxin and Statins:
‘Atrovastatin, fluvastatin and simvastatin
cause minor increases in digoxin levels;
The small changes seen in the digoxin
levels with the statins seem unlikely to be
clinically relevant in most patients.’
The information is based on published
sources including clinical studies, case
reports and systematic reviews so can
be trusted as accurate, evaluated and
evidence-based. Only clinically relevant
information is included in monographs
making it an easy reference to have on
hand in a busy working environment.
Each drug interactions is rated taking
into account the required action to
accommodate the interaction, the
potential severity of the unmanaged
interaction as well as the evidence;
ranging from extensive to theoretical.
These ratings are combined to categorise
each monograph as;
• Interactions with a life threatening
outcome or where use is
• Interactions which may result in a
significant hazard therefore requiring
dose adjustment or close monitoring
• Interactions which may require
provision of adverse effect information
to the patient and/or close monitoring
• Interactions that are not considered
This is a highly recommended reference
for a busy working environment
providing convenient and practical
summary of the comprehensive work of
the popular “Stockleys Drug Interactions”.
Stockley’s Drug Interactions Pocket
Companion 2012, Edited by Karen Baxter,
is available from PSA online at www.psa.
Member price $69
Non-member price $88
Links Archive Australian Pharmacist June 2012 Australian Pharmacist August 2012 Navigation Previous Page Next Page